

# Philippe J Caron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/187285/publications.pdf>

Version: 2024-02-01

69  
papers

2,152  
citations

279798

23  
h-index

233421

45  
g-index

76  
all docs

76  
docs citations

76  
times ranked

1999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. <i>European Journal of Endocrinology</i> , 2005, 152, 757-767.	3.7	160
2	Selenium and the thyroid gland: more good news for clinicians. <i>Clinical Endocrinology</i> , 2013, 78, 155-164.	2.4	159
3	Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1282-1290.	3.6	146
4	Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2849-2853.	3.6	112
5	Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4680-4687.	3.6	111
6	Frequent Large Germline <i>HRPT2</i> Deletions in a French National Cohort of Patients With Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E403-E408.	3.6	107
7	Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. <i>Clinical Endocrinology</i> , 2007, 67, 282-289.	2.4	102
8	Deficient Nocturnal Surge of Thyrotropin in Central Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 62, 960-964.	3.6	99
9	Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. <i>European Journal of Endocrinology</i> , 2008, 158, 305-310.	3.7	93
10	Urinary Iodine Excretion During Normal Pregnancy in Healthy Women Living in the Southwest of France: Correlation with Maternal Thyroid Parameters. <i>Thyroid</i> , 1997, 7, 749-754.	4.5	92
11	Effectiveness and tolerability of 3-year lanreotide Autogel <sup>®</sup> treatment in patients with acromegaly. <i>Clinical Endocrinology</i> , 2006, 64, 209-214.	2.4	63
12	Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. <i>Annales D'Endocrinologie</i> , 2020, 81, 507-510.	1.4	53
13	Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. <i>Endocrine</i> , 2019, 63, 120-129.	2.3	51
14	Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). <i>European Journal of Endocrinology</i> , 1995, 132, 320-325.	3.7	44
15	High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2009, 70, 533-538.	2.4	43
16	Thyroiditis and SARS-CoV-2 pandemic: a review. <i>Endocrine</i> , 2021, 72, 326-331.	2.3	37
17	Combined Hypothalamic-Pituitary-Gonadal Defect in a Hypogonadic Man with a Novel Mutation in the <i>DAX-1</i> Gene1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3563-3569.	3.6	35
18	Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2849-2853.	3.6	32

#	ARTICLE	IF	CITATIONS
19	Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary, 2016, 19, 149-157.	2.9	30
20	Primary Medical Treatment of Thyrotropinâ€‘Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients. Thyroid, 2015, 25, 877-882.	4.5	27
21	Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Medicale, 2019, 48, e199-e207.	1.9	26
22	Sightâ€‘threatening Gravesâ€™ orbitopathy: Twenty yearsâ€™ experience of a multidisciplinary thyroidâ€‘eye outpatient clinic. Clinical Endocrinology, 2019, 90, 208-213.	2.4	26
23	Impact of growth hormone hypersecretion on the adult human kidney. Annales D'Endocrinologie, 2011, 72, 485-495.	1.4	25
24	Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors. Annales D'Endocrinologie, 2018, 79, 569-573.	1.4	25
25	Central hypothyroidism in adults: better understanding for better care. Pituitary, 2015, 18, 169-175.	2.9	24
26	Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management. Endocrine, 2022, 78, 406-417.	2.3	23
27	Ectopic Cushing's syndrome due to a pheochromocytoma: A new case in the post-partum and review of literature. Gynecological Endocrinology, 2009, 25, 624-627.	1.7	22
28	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Annales D'Endocrinologie, 2015, 76, 664-670.	1.4	22
29	Glucose and lipid levels with lanreotide autogel 120 mg in treatmentâ€‘naïve patients with acromegaly: data from the <sc>PRIMARYS</sc> study. Clinical Endocrinology, 2017, 86, 541-551.	2.4	21
30	An update on clinical care for pregnant women with acromegaly. Expert Review of Endocrinology and Metabolism, 2019, 14, 85-96.	2.4	21
31	Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clinical Endocrinology, 2011, 74, 694-698.	2.4	20
32	Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function. Pituitary, 2015, 18, 461-464.	2.9	19
33	Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders. Nuclear Medicine Communications, 2017, 38, 756-763.	1.1	18
34	Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary, 2012, 15, 518-525.	2.9	17
35	Multinodular goitre is a gateway for molecular testing of DICER1 syndrome. Clinical Endocrinology, 2019, 91, 669-675.	2.4	17
36	Covid-19, the thyroid and the pituitaryâ€‘The real state of play. Annales D'Endocrinologie, 2022, 83, 103-108.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Primary sellar melanocytic tumor: report of new case and literature review. <i>Pituitary</i> , 2009, 12, 51-56.	2.9	15
38	Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. <i>Clinical Endocrinology</i> , 2020, 93, 248-260.	2.4	14
39	Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 463-483.	5.7	14
40	Neurocognitive outcomes of children secondary to mild iodine deficiency in pregnant women. <i>Annales D'Endocrinologie</i> , 2015, 76, 248-252.	1.4	13
41	Gestational diabetes and acromegaly: Single-centre experience of 14 pregnancies. <i>Clinical Endocrinology</i> , 2019, 91, 805-809.	2.4	12
42	What Is the Quality of Life in Patients Treated with Levothyroxine for Hypothyroidism and How Are We Measuring It? A Critical, Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1386.	2.4	12
43	Virilising ovarian tumour: a case associating a Sertoli-Leydig cell tumour and a Brenner tumour. <i>Gynecological Endocrinology</i> , 2011, 27, 345-350.	1.7	10
44	Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. <i>Pituitary</i> , 2012, 15, 23-27.	2.9	9
45	Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus statement 2019. Long version. <i>Annales D'Endocrinologie</i> , 2020, 81, 89-100.	1.4	9
46	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. <i>Endocrine</i> , 2021, 71, 158-167.	2.3	8
47	Is MRI follow-up relevant in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogues (SMSa)? <i>European Journal of Endocrinology</i> , 2020, 182, 123-130.	3.7	7
48	Virilizing oncocytic adrenocortical carcinoma: clinical and immunohistochemical studies. <i>Gynecological Endocrinology</i> , 2016, 32, 662-666.	1.7	6
49	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) $T_j ETQq1 1.0,784314,rgBT / O_{1.4}$	1.4	6
50	New variant (Val597Ile) in transmembrane region of the TSH receptor with human chorionic gonadotropin hypersensitivity in familial gestational hyperthyroidism. <i>Clinical Endocrinology</i> , 2020, 93, 339-345.	2.4	6
51	Orbital inflammatory disease following mRNA SARS-CoV-2 vaccine. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.5	6
52	New therapies for patients with multiple endocrine neoplasia type 1. <i>Annales D'Endocrinologie</i> , 2021, 82, 112-120.	1.4	5
53	Inherited Selenocysteine Transfer RNA Mutation: Clinical and Hormonal Evaluation of 2 Patients. <i>European Thyroid Journal</i> , 2021, 10, 542-547.	2.4	5
54	Management of thyrotoxicosis and pregnancy: Review of the current literature and an update of the care pathway. <i>Annales D'Endocrinologie</i> , 2022, 83, 226-231.	1.4	5

#	ARTICLE	IF	CITATIONS
55	IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3644-e3653.	3.6	5
56	First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly. <i>Endocrine</i> , 2020, 70, 396-403.	2.3	4
57	Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus 2019 guidelines. Short version. <i>Annales D'Endocrinologie</i> , 2020, 81, 511-515.	1.4	4
58	Severe thyrotoxicosis in an infant revealing familial nonautoimmune hyperthyroidism with a novel (C672W) stimulating thyrotropin receptor germline mutation. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1980-1987.	0.5	3
59	Medical therapy in patients with endogenous hypoglycaemia: Is euglycaemia achievable?. <i>Clinical Endocrinology</i> , 2019, 90, 798-804.	2.4	3
60	Lanreotide Autogel <sup>®</sup> in acromegaly and neuroendocrine tumors. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 9-29.	0.2	2
61	Effect of orbital radiotherapy on the outcome of surgical orbital decompression for thyroid-associated orbitopathy (TAO): a retrospective study in 136 patients. <i>Endocrine</i> , 2020, 67, 605-612.	2.3	2
62	MRI follow-up of patients with acromegaly being treated with first-generation somatostatin receptor ligands after surgery. <i>Clinical Endocrinology</i> , 2022, 97, 686-688.	2.4	2
63	The DIAGONALE study: A survey designed to analyze the diagnosis and management of goiter in France. <i>Annales D'Endocrinologie</i> , 2012, 73, 202-207.	1.4	1
64	2011 Consensus of the French Endocrine Society: "Hypoglycaemia in non-diabetic adult patients". <i>Annales D'Endocrinologie</i> , 2013, 74, 166-167.	1.4	1
65	Local recurrence of pheochromocytoma in multiple endocrine neoplasia type 2A: a diagnostic and therapeutic challenge. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 298-300.	0.5	1
66	Central hypothyroidism during pregnancy in a woman with Graves' disease. <i>Clinical Endocrinology</i> , 2022, 96, 89-91.	2.4	1
67	Pituitary Adenomas, TSH-Secreting. , 2004, , 624-628.		0
68	Traitement des dysthyroïdies. , 2018, , 361-377.e1.		0
69	Thyroïde et grossesse Prise en charge diagnostique et thérapeutique de l'hypothyroïdie et l'hyperthyroïdie au cours de la grossesse. , 2022, , 231-246.		0